Lorenzi A - Search Results

1

Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implications.

Corso A, Zappasodi P, Pascutto C, Bosoni T, Mangiacavalli S, Lorenzi A, Rusconi C, Lazzarino M. Corso A, et al. Among authors: lorenzi a. Ann Hematol. 2003 Aug;82(8):487-491. doi: 10.1007/s00277-003-0699-9. Epub 2003 Jul 1. Ann Hematol. 2003. PMID: 12838370

2

Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.

Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, Passamonti F, Klersy C, Pascutto C, Canevari-Sciorati A, Lazzarino M. Corso A, et al. Among authors: lorenzi a. Haematologica. 2001 Apr;86(4):394-8. Haematologica. 2001. PMID: 11325645

3

Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone.

Corso A, Lorenzi A, Terulla V, Airò F, Varettoni M, Mangiacavalli S, Zappasodi P, Rusconi C, Lazzarino M. Corso A, et al. Among authors: lorenzi a. Ann Hematol. 2004 Sep;83(9):588-91. doi: 10.1007/s00277-004-0891-6. Epub 2004 Jul 3. Ann Hematol. 2004. PMID: 15235749

4

A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.

Corso A, Arcaini L, Caberlon S, Zappasodi P, Mangiacavalli S, Lorenzi A, Rusconi C, Troletti D, Maiocchi MA, Pascutto C, Morra E, Lazzarino M. Corso A, et al. Among authors: lorenzi a. Haematologica. 2002 Oct;87(10):1041-5. Haematologica. 2002. PMID: 12368158

5

Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection.

Corso A, Varettoni M, Mangiacavalli S, Zappasodi P, Klersy C, Rusconi C, Colucci E, Lorenzi A, Troletti D, Consensi E, Lazzarino M. Corso A, et al. Among authors: lorenzi a. Leuk Res. 2005 Feb;29(2):159-63. doi: 10.1016/j.leukres.2004.05.018. Leuk Res. 2005. PMID: 15607364

6

The irreplaceable image. Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity.

Zappasodi P, Lorenzi A, Corso A. Zappasodi P, et al. Among authors: lorenzi a. Haematologica. 2001 Apr;86(4):448. Haematologica. 2001. PMID: 11325662 No abstract available.

7

Advantages of using thalidomide for the management of refractory myeloma patients.

Corso A, Lorenzi A, Orlandi E, Astori C, Mangiacavalli S, Lazzarino M. Corso A, et al. Among authors: lorenzi a. Haematologica. 2002 Mar;87(3):327-8. Haematologica. 2002. PMID: 11869949

8

Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.

Corso A, Lorenzi A, Zappasodi P, Invernizzi R, Vanelli L, Lazzarino M. Corso A, et al. Among authors: lorenzi a. Haematologica. 2003 Aug;88(8):958-60. Haematologica. 2003. PMID: 12935985 Review. No abstract available.

9

A young woman with microcytic anemia and hypertransaminasemia.

Arcaini L, Cerani P, Lorenzi A, Lazzarino M. Arcaini L, et al. Among authors: lorenzi a. Haematologica. 2001 Oct;86(10):E24. Haematologica. 2001. PMID: 11602431 No abstract available.

10

Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse.

Bonfichi M, Balduini A, Arcaini L, Lorenzi A, Marseglia C, Malcovati L, Bernardi L, Passino C, Spandacini G, Feil P, Keyl C, Schneider A, Boiardi A, Bandinelli G, Greene RE, Bernasconi C. Bonfichi M, et al. Among authors: lorenzi a. Br J Haematol. 2000 Jun;109(4):895-6. doi: 10.1046/j.1365-2141.2000.109004895.x. Br J Haematol. 2000. PMID: 10970133 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136 results

Search Page

Filters